Literature DB >> 9072845

[The conformal radiotherapy of localized prostatic carcinoma: acute tolerance and early efficacy].

D Zierhut1, M Flentje, G Sroka-Perez, V Rudat, R Engenhart-Cabillic, M Wannenmacher.   

Abstract

AIM: In a prospective trial early effectiveness and acute toxicity of conformal 3D-planned radiotherapy for localized prostate cancer was quantified using dose-volume-histogramms and evaluated with respect of treatment technique. PATIENTS AND
METHOD: Thirty-two men (44 to 80 years old) with locally advanced carcinoma of the prostate (stage B2 or C) have been treated by 3D-planned conformal radiotherapy using high energy photons. In 28/32 men treatment technique was a monoaxial bisegmental rotation with irregular fields. With single doses of 2.0 Gy a mean total dose of 63.9 +/- 4.9 Gy according to ICRU was applied within 46 +/- 4 days. Maximum dose was in the mean 105.1% +/- 3.8%. 3D treatment volume was 274.1 +/- 113.4 cm3. Median follow-up is 1.8 years (15 to 34 months). Toxicity was evaluated according to RTOG-EORTC by patient interview and physical examination on a weekly basis during radiotherapy and by regular follow-up.
RESULTS: Eleven patients had none, 15 mild (RTOG grade 1) and 6 moderate symptoms (RTOG grade 2, mainly diarrhoea, dysuria and polyuria). Acute complications leading to treatment interruption did not occur. In 16 patients symptoms disappeared within 6 weeks after radiotherapy. Only 2 men had symptoms which lasted longer than 3 months and were endoscopically examined. Up to now no late complications were detected. Incidence and severity of toxicity was significantly (p < 0.05) related to the size of treatment volume. Acute toxicity was found to depend statistically significant (p < 0.05) on the proportional volume of bladder and rectum, irradiated with more than 35 Gy. In 81% of the patients with pretherapeutic elevated PSA levels normalisation of PSA was observed. Overall mean PSA levels of 15.7 +/- 22.6 micrograms/l at the beginning of radiotherapy fell to 2.1 +/- 3.7 micrograms/l 6 weeks after irradiation. Only 1 Patient relapsed locally 22 months after radiation therapy.
CONCLUSION: We conclude that due to modern 3D-planned conformal techniques with optimization of treatment dose and improved protection of critical organs such as urinary bladder and rectum, radiotherapy allows an effective and well tolerated therapy of localized prostatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9072845     DOI: 10.1007/BF03038929

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   4.033


  50 in total

1.  Therapeutic Options for Clinically Localized Carcinoma of the Prostate.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1993-07       Impact factor: 5.934

2.  Current Status of Prostate-Specific Antigen in the Radiotherapeutic Management of Prostatic Cancer.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1993-07       Impact factor: 5.934

3.  Monitoring of prostate-specific antigen during external beam radiotherapy for carcinoma of the prostate.

Authors:  M van Eijkeren; J P van Haelst
Journal:  Strahlenther Onkol       Date:  1990-08       Impact factor: 3.621

4.  Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.

Authors:  K J Russell; C Dunatov; M D Hafermann; J T Griffeth; L Polissar; J Pelton; S B Cole; E W Taylor; L W Wiens; W J Koh
Journal:  J Urol       Date:  1991-10       Impact factor: 7.450

5.  Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate.

Authors:  S A Leibel; G E Hanks; S Kramer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-03       Impact factor: 7.038

6.  Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: preliminary results of a phase I dose-escalation study.

Authors:  S A Leibel; R Heimann; G J Kutcher; M J Zelefsky; C M Burman; E Melian; J P Orazem; R Mohan; T J LoSasso; Y C Lo
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-01       Impact factor: 7.038

7.  Comparison of a conformal nonaxial boost with a four-field boost technique in the treatment of adenocarcinoma of the prostate.

Authors:  C F Mesina; R Sharma; L S Rissman; L Geering; T He; J D Forman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-09-30       Impact factor: 7.038

8.  Tumor control in definitive irradiation of localized carcinoma of the prostate.

Authors:  A A Perez; M V Pilepich; F Zivnuska
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

9.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.

Authors:  G K Zagars; A Pollack; V S Kavadi; A C von Eschenbach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-05-15       Impact factor: 7.038

10.  PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation.

Authors:  G E Hanks; C A Perez; M Kozar; S O Asbell; M V Pilepich; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-09-30       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.